These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 2678128)

  • 1. Selective stimulation of renal PGE2 by potassium canrenoate in essential hypertension.
    Castellani S; Scarti L; Masotti G; Del Rosso A; Chen JI; Neri Serneri GG
    Prog Clin Biol Res; 1989; 301():297-301. PubMed ID: 2678128
    [No Abstract]   [Full Text] [Related]  

  • 2. The antihypertensive and renal activities of potassium canrenoate are associated with increased renal prostaglandin excretion.
    Castellani S; Scarti L; Chen JL; Del Rosso A; Carnovali M; Masotti G
    Clin Sci (Lond); 1989 Aug; 77(2):217-22. PubMed ID: 2766661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical study of the efficacy of oral potassium canrenoate and spironolactone in essential arterial hypertension].
    Tosti-Croce C; Mantellini R; Fanti P; Sciarra F
    Minerva Med; 1983 Apr; 74(14-15):791-7. PubMed ID: 6339999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of furosemide, potassium canrenoate and D-L-propranolol on blood pressure in spontaneously hypertensive rat].
    Altman J; Gordan P; Grünfeld JP
    Pathol Biol (Paris); 1976 May; 24(5):337-41. PubMed ID: 781602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Interference of canrenoate potassium with plasma renin activity. Note I. Effects of canrenoate potassiumon plasma renin activity in patients with essential hypertension].
    Consolo F; Ferraù O; Pitrone F; Luzza G; Russo A; Virga T
    Boll Soc Ital Biol Sper; 1975 Dec; 51(24):1943-9. PubMed ID: 1231877
    [No Abstract]   [Full Text] [Related]  

  • 6. Spirolactones: clinical and pharmacologic studies.
    Corvol P; Claire M; Rafestin-Oblin ME; Michaud A; Roth-Meyer C; Menard J
    Adv Nephrol Necker Hosp; 1977; 7():199-215. PubMed ID: 208407
    [No Abstract]   [Full Text] [Related]  

  • 7. Sodium excretion and sodium-free volume expansion in dogs: effect of inhibition of aldosterone activity by canrenoate.
    Bie P
    Acta Physiol Scand; 1976 Oct; 98(2):272-4. PubMed ID: 983738
    [No Abstract]   [Full Text] [Related]  

  • 8. [Antihypertensive efficacy and effects on intra and extracellular electrolytes of a canrenoate potassium-butizide combination].
    Costa FV; Borghi C; Mussi A; Ambrosioni E
    Minerva Cardioangiol; 1988 Oct; 36(10):503-7. PubMed ID: 3226562
    [No Abstract]   [Full Text] [Related]  

  • 9. Plasma digoxin radioimmunoassay in patients treated with potassium canrenoate and spironolactone. A comparison of two commerical kits.
    Cristodorescu R; Gavrilescu S; Deutsch G; Berger E
    Agressologie; 1978; 19(6):409-14. PubMed ID: 751526
    [No Abstract]   [Full Text] [Related]  

  • 10. Combination therapy with enalapril and hydrochlorothiazide: optimal dose, renin response, and prostaglandin excretion.
    Mittman N; Dubrow A; Westerman M; Flamenbaum W
    J Clin Hypertens; 1986 Mar; 2(1):30-8. PubMed ID: 3014080
    [No Abstract]   [Full Text] [Related]  

  • 11. [Effect of potassium canrenoate on arterial pressure, plasma renin activity and urinary aldosterone in essential hypertension].
    Opocher G; Armanini D; Fallo F; Mantero F
    Boll Soc Ital Cardiol; 1978; 23(10):1757-66. PubMed ID: 400390
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative clinical study of spironolactone and potassium canrenoate. A randomized evaluation with double cross-over.
    Emili M; Cuppone R; Ricci GL
    Arzneimittelforschung; 1988 Oct; 38(10):1492-5. PubMed ID: 3058132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostacyclin synthesis is increased during propranolol therapy for essential hypertension.
    Beckmann ML; Nies AS; Gerber JG
    Adv Prostaglandin Thromboxane Leukot Res; 1989; 19():203-6. PubMed ID: 2526468
    [No Abstract]   [Full Text] [Related]  

  • 14. [Cardiac and selective vascular effects of canrenoate-potassium (aldactone pro injectione) in cardiosurgical patients (author's transl)].
    Piepenbrock S; Hempelmann G; Volkholz E; Oelert H
    Prakt Anaesth; 1977 Oct; 12(5):400-12. PubMed ID: 917981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different sensitivity to hydrochlorothiazide and to potassium-canrenoate among essential hypertensive patients.
    Glorioso N; Melis MG; Manunta P; Troffa C; Tonolo G; Soro A; Madeddu P; Pazzola A; Pala F; Cusi D
    Clin Exp Hypertens; 1993; 15 Suppl 1():187-96. PubMed ID: 8513309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of Aldatense on laboratory tests. Comparison with a reference population].
    Hitz J; Steinmetz J; Henny J; Siest G
    Ann Biol Clin (Paris); 1984; 42(4):289-93. PubMed ID: 6149712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind crossover study of fenquizone compared to chlorthalidone in essential hypertension.
    Angelino PF; Alvino-Demartino A; Mappa R; Donati C
    Int J Clin Pharmacol Ther Toxicol; 1985 Sep; 23(9):501-5. PubMed ID: 3902676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute natriuretic effect of nifedipine on different sodium intakes in essential hypertension: evidence for distal tubular effect?
    Cappuccio FP; Antonios TF; Markandu ND; Folkerd EJ; Sagnella GA; Sampson B; MacGregor GA
    J Hum Hypertens; 1994 Aug; 8(8):627-30. PubMed ID: 7990097
    [No Abstract]   [Full Text] [Related]  

  • 19. Antihypertensive and hypokalemic effects of isobutyl hydrochlorothiazide alone and in combination with spironolactone.
    Lochaya S; Suvachittanont O; Triyanond K
    J Med Assoc Thai; 1985 Aug; 68(8):399-407. PubMed ID: 3906011
    [No Abstract]   [Full Text] [Related]  

  • 20. Atenolol and chlorthalidone administered alone and in combination for essential hypertension.
    Boike SC; Durley Y; Cubberley RB
    Clin Pharm; 1982; 1(5):449-53. PubMed ID: 6764166
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.